Novo Nordisk (NVO) has reportedly settled a lawsuit filed by the state of Minnesota over the pricing of its insulin products by agreeing to cap costs at $35 per month.

The settlement resolves the Attorney General’s 2018 lawsuit alleging that Novo Nordisk deceptively priced its insulin.

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

In absolute terms, there were 0.73 cases of hypoglycaemia per year with insulin icodec, versus 0.27 events for the once-daily drug. Novo Nordisk said that if approved for use, insulin icodec would ...

It has been estimated that 90% of medical device waste consists of single-use products or components, so a new initiative by Novo Nordisk to recycle pre-filled injection pens used by people living ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Subcutaneous Drug Delivery Devices Market To Reach USD 56.95 Billion By 2032, Growing At A CAGR Of 7.07% - SNS Insider Subcutaneous Drug Delivery Devices market Growth Fueled by Chronic Diseases and ...

Although no randomized clinical trials using U-500 insulin have been performed, eight case series (involving ... Actrapid U-500, Novo Nordisk in the United Kingdom [voluntarily withdrawn in ...

Novo Nordisk announced phase 1b/2a clinical trial results for amycretin this morning. Patients taking the GLP-1 drug lost an average of 9.7% of their weight in 36 weeks. This is the best news Novo ...

Finally, some good news for Novo Nordisk (NYSE: NVO) shareholders! Twice in the past two months, the Danish manufacturer of GLP-1 drugs for weight loss and diabetes treatment has reported clinical ...

Get the Real Story Behind Every Major Earnings Report On Friday, Novo Nordisk A/S NVO released topline results from a phase 1b/2a trial with amycretin intended for once-weekly subcutaneous ...